Article Text

Download PDFPDF

Drug therapy in chronic heart failure
  1. O Jolobe
  1. Manchester, UK;

    Statistics from

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    In their recent paper on drug therapy in chronic heart failure the authors addressed all the important issues.1 Blood volume depletion (mediated by drug related augmentation of diuresis) complicates “triple therapy” when spironolactone is co-prescribed with loop diuretics and angiotensin converting enzyme inhibitors.2–4 Therefore, over and above the recommendation to check renal function and potassium levels, I would add that patients on triple therapy should have strict monitoring of their daily weight so as to pre-empt prerenal uraemia by appropriate titration of diuretic dosage.